Company: LIDRW
Filing Date: 2025-02-25
Form Type: S-1/A
Source: 0000947871-25-000220
Chunk: 15

Company: AEye, Inc.
Filing Date: 2025-02-25
Form: S-1/A
Chunk 15
---
4670 Willow Road, Suite 125, Pleasanton, CA 94588.

| 10 |

THE OFFERING

| Shares of Common Stock offered by the Selling Stockholders | Up to 9,638,718 shares of the Common Stock,                                                                                                                                                                                                                                                                                                     
 which consist of:                                                                                                                                                                                                                                                                                                                               
 (i) 330,823 shares of Common Stock constituting the                                                                                                                                                                                                                                                                                             
 Dowslake Shares;                                                                                                                                                                                                                                                                                                                                
 (ii) up to 8,100,000 shares of Common Stock issuable                                                                                                                                                                                                                                                                                            
 pursuant to the terms of the Convertible Note; and                                                                                                                                                                                                                                                                                              
 (iii) up to 1,207,895 shares of Common Stock issuable                                                                                                                                                                                                                                                                                           
 upon exercise of the Warrant.                                                                                                                                                                                                                                                                                                                   |
| Shares of Common Stock                                     
 outstanding prior to this offering                         | 18,689,669 shares of our Common Stock outstanding                                                                                                                                                                                                                                                                                               
 on February 20, 2025.                                                                                                                                                                                                                                                                                                                           |
| Use of proceeds                                            | We are not selling any shares of Common Stock under this prospectus and will not receive any of the proceeds from the sale of shares of Common Stock by the Selling Stockholders. We will receive any proceeds from the cash exercise of the Warrant (if any), but not from the sale of the shares of Common Stock issuable upon such exercise. |
| Risk factors                                               | Investing in our Common                                                                                                                                                                                                                                                                                                                         
 Stock involves a high degree of risk. You should carefully read the “Risk Factors” beginning on page 12 and the                                                                                                                                                                                                                                 
 other information included or incorporated by reference in this prospectus for a discussion of factors you should consider carefully                                                                                                                                                                                                            
 before deciding to invest in our Common Stock.                                                                                                                                                                                                                                                                                                  |
| Nasdaq symbol for our Common Stock                         | “LIDR”                                                                                                                                                                                                                                                                                                                                          |

| 11 |

<div align='center'>RISK FACTORS</div>

An investment in the Common Stock involves
a high degree of risk. Before you decide to invest in shares of Common Stock, you should consider carefully all of the information in
this prospectus and the documents incorporated by reference herein and, in particular, the risks described below and the Risk Factors
included in any prospectus supplement or amendment, our Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequently
filed Quarterly Reports on Form 10-Q and our other filings with the SEC that are incorporated by reference into this prospectus. The
risks described in this prospectus or